(UroToday.com) At the 2021 EAU annual meeting, Dr. Klara Kvorning Ternov presented data from the HEAT randomized trial assessing fatigue, quality-of-life and metabolic changes in men treated with enzalutamide versus abiraterone + prednisone. Men with metastatic castration-resistant prostate cancer (mCRPC) often experience fatigue, impaired quality of life and have an increased risk of cardiovascular disease and type 2 diabetes mellitus. These highly burdensome symptoms and the increased risk of morbidity are often treatment associated and may be reduced by opting for a particular treatment. In this study, fatigue, quality of life and metabolic changes were compared between enzalutamide and abiraterone acetate plus prednisone.